OptiBiotix Health plc
("OptiBiotix" or the "Company")
PDMR Dealing
Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.
Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
| OptiBiotix Health plc | ||
| Neil Davidson, Chairman | Contact via Walbrook below | |
| Stephen O'Hara, Chief Executive |
| |
|
|
| |
| Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti |
| |
|
|
| |
| Cenkos Securities plc (Broker) | Tel: 020 7397 8900 | |
| Callum Davidson / Neil McDonald |
| |
| Michael Johnson / Russell Kerr (Sales) |
| |
|
|
| |
| Walbrook PR Ltd | Mob: 07876 741 001 | |
| Anna Dunphy |
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | René Kamminga | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | PDMR | |||||
| b. | Initial notification/ Amendment | Initial Notification | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | OptiBiotix Health Plc | |||||
| b. | LEI | 213800UKYQFT941QHS14 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | 8,188 ordinary shares of 2p each
ISIN: GB00BP0RTP38 | |||||
| b. | Nature of the transaction | Purchase of 8,188 ordinary shares in the Company
| |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) per share | Volume(s) |
| ||||
| 55.4p | 8,188 |
| |||||
|
| |||||||
| d. | Aggregated information - Volume - Price |
n/a | |||||
| e. | Date of the transaction | 31 August 2021 | |||||
| f. | Place of the transaction | London Stock Exchange, AIM | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
